Heart Failure to Success

Link to articleLanger H, Gilmore N, Hayden C ...Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humansCell Reports Medicine, 7https://doi.org/10.1016/j.xcrm.2026.102665

Padmashri Prof. I. Sathiyamurthy Discusses Hypotension in HFrEF - Importance and Management with Dr. D. Prabhakar

Prof. Peter Van Der Meer member of the working group of Peripartum Cardiomyopathy of ESC discusses Peripartum Cardiomyopathy- prevalence, caution, management and longterm data with Dr.D.Prabhakar at the HFAI 2026, Ahemedabad

Cardiac rehabilitation in Heart Failure.. explained by Dr.Dilip Kumar to Dr.D.Prabhakar at the HFAI 2026 at Ahemedabad

The National Heart Failure Registry one year aetiology wise outcomes are discussed by Dr. Harikrishnan with Dr. D. Prabhakar

Abraham Oomman discusses the heart failure with improved Ejection fraction.. the terminologies, the markers, the present and the future with Dr. D. Prabhakar

Curtain raiser for HFAI Annual Conference 2026 at Ahemedabad

WITHDRAW-AF trial discusses the withdrawal of GDMT in patients with AF and HFrEF that have improved their ejection fraction following restoration of sinus rhythm. Should GDMT be continued or can it be stopped and in whom ?Read the full articlehttps://doi.org/10.1093/eurheartj/ehaf563

PARAGON- HF trial noted a BMI >=30 in 49% whereas Waist-Height ratio >= 0.5 was recorded in 96%.. BMI showed an obesity paradox while Waist height ratio did not. Read the full article https://doi.org/10.1093/eurheartj/ehaf057

Why do we need one ? The definition, Staging and Classification based on LV Ejection fraction. Out with the old and In with the new terminologies

The basic definition of HFimpEF, and withdrawal of therapy here are discussed. The traditionally quoted trial is the TRED HF trial. A new trial called the CATHEDRAL trial using only carvedilol rather than complete withdrawal was similar to continuation of treatment. The clinical implications, and future of HFimpEF are discussed by Dr. Prabhakar Dorairaj.

Cardiac rehabilitation part 2 - focus on heart failure.. Dr. D.Prabhakar discusses with Dr. Lakshmi Nair

Dear friends, welcome to the first part of our two-part cardiac rehabilitation series! Dr. Aruna, Consultant Cardiologist at Apollo Hospitals, interviews Dr. Lakshmi Nair, Head of the Department of Cardiac Rehabilitation.In this Q&A session, they discuss:✅ The historical context and level of evidence for cardiac rehab✅ Who can benefit — potential candidates for cardiac rehabilitation✅ The core components of an effective CR program✅ India’s current status in cardiac rehabilitation

Cardio-oncology is developing into an enigmatic new field. More questions from the oncologists and cardiologists alike are asked. In this episode, we discuss the cross connection between oncology and heart failure, the common soil hypothesis and the ways to curtail both heart disease and cancers

Demystifying the use of Mineralocorticoid Receptor Antagonists(MRAs) in HFpEF. Spironolactone and the TOPCAT trial in HFpEF are reported negative but trial is mired with some controversies that is discussed. Future trials previewed. Steroidal and nonsteroidal MRAs simplified. Finerenone is the new MRA - the FINE ART trial and the FINEHEART meta - analysis efficacy and safety are outlined.Finally an approach to the management of HFpEF in clinical practice.

In this episode of Heart Failure to Success, we discuss the growing challenge of heart failure in India and how physicians can make a difference. Our experts share practical insights on guideline-based treatment, the role of advanced therapies, and real-world clinical strategies to improve patient outcomes. Tune in to gain knowledge that empowers your practice and supports better care for patients with heart failure.